Verrica Pharmaceuticals Inc. VRCA
Set alert
As of Nov 2, 2:51 PM ET
- YTD
- -60.17%
- 1 year
- -8.31%
- Open
- 3.40
- Prev close
- 3.35
- Mkt cap
- 56.86M
- Vol
- 38.72K
- Avg vol
- 69.92K
- EPS
- -1.75
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 3.29
- High
- 3.54
- Forward P/E
- -1.19
- Beta
- 1.46
- Short ratio
- 3.19
- Inst. own
- 15.80%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Aug 14, 2024
- 50-d avg
- 1.12
- 200-d avg
- 4.58
- 1y target
- 6.33
Key statistics
- Market cap
- 63.71M
- Enterprise value
- 55.81M
- Trailing P/E
- 0.00
- Forward P/E
- -1.19
- PEG ratio
- 0.00
- Price / sales
- 6.92
- Price / book
- 0.00
- EPS (TTM)
- -1.84
- Beta
- 1.46
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 9.21M
- Revenue growth
- 0.00%
- Free cash flow
- -31.81M
- Total cash
- 22.96M
- Total debt
- 47.11M
- Return on equity
- -2059.89%
- Shares outstanding
- 90.56M
- Short % of float
- 4.54%
- 50-day average
- 1.12
- 200-day average
- 4.58
Analyst view
Consensus: buy
- Target (low)
- 2.00
- Target (mean)
- 6.33
- Target (high)
- 12.00
- Strong buy0
- Buy2
- Hold4
- Sell0
- Strong sell0
Next earnings
Aug 14, 2024
Expected Aug 14, 2024. Consensus EPS estimate -0.284.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 4, 2024 | Sep 1, 2024 | -0.37 | -0.49 | -0.12 | -32.43% |
| Aug 14, 2024 | Jun 1, 2024 | -0.43 | -0.31 | +0.12 | +27.91% |
| Aug 14, 2024 | Jun 1, 2024 | -0.43 | — | — | — |
| May 13, 2024 | Mar 1, 2024 | -0.54 | -0.38 | +0.16 | +29.63% |
| May 13, 2024 | Mar 1, 2024 | -0.54 | — | — | — |
| Feb 29, 2024 | Dec 1, 2023 | -0.47 | -0.48 | -0.01 | -2.13% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Dec 20, 2024 | Needham | reit | Hold | Hold |
| Nov 6, 2024 | HC Wainwright & Co. | down | Buy | Neutral |
| Nov 5, 2024 | Needham | reit | — | Hold |
| Nov 5, 2024 | RBC Capital | down | Outperform | Sector Perform |
| Oct 21, 2024 | TD Cowen | main | Buy | Buy |
| Oct 4, 2024 | RBC Capital | main | Outperform | Outperform |
About Verrica Pharmaceuticals Inc.
Verrica Pharmaceuticals Inc., a clinical-stage dermatology therapeutics company, develops medications for the treatment of skin diseases in the United States. Its product pipeline comprises YCANTH (VP-102), which is in phase III clinical trial for the treatment of common warts; and has completed phase II clinical trial for the treatment of external genital warts. The company also develops VP-315, an oncolytic peptide-based injectable therapy, which is in phase II clinical trial for the treatment of dermatology oncologic conditions which includes basal cell carcinoma; and VP-103, a cantharidin-based product candidate for the treatment of plantar warts and is in phase II clinical trial. In addition, it offers YCANTH for the treatment of molluscum contagiosum. The company has a collaboration and license agreement with Torii Pharmaceutical Co., Ltd. for the development and commercialization of its product candidates for the treatment of molluscum contagiosum and common warts in Japan, including VP-102; and a license agreement with Lytix Biopharma AS to develop and commercialize VP-315 for dermatological oncology indications, such as non-metastatic melanoma and non-metastatic merkel cell carcinoma. Verrica Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in West Chester, Pennsylvania.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- verrica.com
News
- Verrica Pharmaceuticals Announces Achievement of Milestones Unlocking Access to the Full $27.5 Million of Non-Dilutive Growth Capital Under Credit Facility
- Verrica Pharmaceuticals Q2 2026 Earnings Call Transcript
- Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Stock Has Average Price Target of $12.67 According to Brokerages
- Verrica Pharmaceuticals to Present New YCANTH® Data Analysis at Two Upcoming Dermatology Conferences
- Verrica Pharmaceuticals to Present YCANTH® and VP-315 Data at Two Upcoming Dermatology Conferences
- Verrica Pharmaceuticals to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
- Verrica Pharmaceuticals Announces Completion of Enrollment in First Pivotal Phase 3 Trial (COVE-2) Evaluating YCANTH® for the Treatment of Common Warts, with Topline Data Expected Q1 2027
- Verrica Pharmaceuticals Q2 Earnings Call Highlights
- Verrica Pharmaceuticals Inc. (VRCA) Q2 2026 Earnings Call Transcript
- Verrica Pharmaceuticals Q2 Adj. EPS $(0.48) Misses $(0.38) Estimate, Sales $5.862M Beat $5.733M Estimate
Your note
Sign in to keep a note on VRCA — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BONACCORSO JOE | Officer | Sale | Aug 26, 2024 | 73,114 |
| GOLDENBERG GARY | Officer | Sale | Aug 26, 2024 | 94,261 |
| HAYES CHRISTOPHER G | Officer | Sale | Aug 26, 2024 | 105,773 |
| KIRBY JOHN J. | Chief Financial Officer | Stock Award(Grant) | Nov 5, 2024 | 54,267 |
| KOHLER TERRY | Chief Financial Officer | Sale | Aug 26, 2024 | 44,697 |
| MANNING PAUL B. | Director and Beneficial Owner of more than 10% of a Class of Security | Stock Gift | Nov 25, 2024 | 38,060,800 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Perceptive Advisors Llc | 15.57% | 7,099,182 | 4.99M | Sep 29, 2024 |
| Vanguard Group Inc | 2.82% | 1,286,600 | 905.12K | Sep 29, 2024 |
| Blackrock Inc. | 2.38% | 1,085,439 | 763.61K | Sep 29, 2024 |
| FMR, LLC | 1.39% | 634,310 | 446.24K | Sep 29, 2024 |
| State Street Corporation | 1.12% | 512,821 | 360.77K | Sep 29, 2024 |
| Geode Capital Management, LLC | 1.00% | 455,480 | 320.43K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 1.79% | 815,893 | 573.98K | Sep 29, 2024 |
| iShares Russell 2000 ETF | 1.19% | 540,966 | 380.57K | Oct 30, 2024 |
| Fidelity Select Portfolios - Biotechnology | 1.14% | 517,629 | 364.15K | Oct 30, 2024 |
| Vanguard Extended Market Index Fund | 0.63% | 289,249 | 203.49K | Sep 29, 2024 |
| Simplify Exchange Traded Fds-Simplify Propel Opportunities ETF | 0.44% | 200,000 | 140.70K | Sep 29, 2024 |
| Fidelity Small Cap Index Fund | 0.43% | 196,507 | 138.24K | Aug 30, 2024 |